LIST OF TABLES

No.	Table Name	Page No.
1.1.	Substrate specificity and tissue distribution of MAO isozymes	9
1.2.	Comparison of amino acid residues involved in the formation of active site of human MAO-A and MAO-B	16
1.3.	(A) Non-selective MAO-A/MAO-B inhibitors (B) Selective MAO-A inhibitors (C) Selective MAO-B inhibitors (D) Molecules in clinical trials	17-19
1.4.	Localization and function of AChE	22
4.1.	Structural data of heterocyclic fragments (**ISN-1** to **ISN-3**)	92
4.2.	Structural data of 2-amino-6-nitrobenzothiazole derived extended hydrazones (**BTA-1** to **BTA-30**)	94-96
4.3.	Physicochemical characterization data of **ISN-1** to **ISN-3**, **BTE** and **BTH**	98
4.4.	Physicochemical characterization data of **BTA-1** to **BTA-30**	98-100
4.5.	Structural data of 2-amino-5-nitrothiazole derived semicarbazones (**NTA-1** to **NTA-18**)	146-147
4.6.	Physicochemical characterization data of **NTA-1** to **NTA-18**	147-148
4.7.	Structural data of 3,4-(methylenedioxy)aniline derived semicarbazones (**MDA-1** to **MDA-14**)	168-169
4.8.	Physicochemical characterization data of **MDA-1** to **MDA-14**	169-170
4.9.	Structural data of 3-hydroxy-3-substituted oxindole analogues of isatin (**HPO-1** to **HPO-14**)	191
4.10.	Physicochemical characterization data of **HPO-1** to **HPO-14**	192
5.1.	*In-vitro* and computational MAO inhibition data for **BTA-1** to **BTA-30**	210-211
5.2.	*In-vitro* and computational AChE inhibition data for **BTA-1** to **BTA-30**	222-223
5.3.	Neurotoxicity screening results of selected compounds of **BTA** series	234
5.4.	Antioxidant activity of selected compounds of **BTA** series	235
5.5.	Estimation of biochemical parameters of compound **BTA-29**	236
5.6.	*In-silico* drug-likeness prediction studies for **BTA-1** to **BTA-30**	237-238
5.7.	*In-silico* ADME prediction data of compounds **BTA-1** to **BTA-30**	239-241

5.8.	*In-silico* toxicity prediction data of compounds **BTA-1** to **BTA-30**	242-243
5.9.	*In-vitro* and computational MAO inhibition data for **NTA-1** to **NTA-18**	247-248
5.10.	*In-vitro* and computational AChE inhibition data for **NTA-1 to NTA-18**	258-259
5.11.	Neurotoxicity screening results of selected compounds of **NTA** series	267
5.12.	Antioxidant activity of selected compounds of **NTA** series	267-268
5.13.	Estimation of biochemical parameters of **NTA-1** and **NTA-18**	268-269
5.14.	*In-silico* prediction of drug-likeness for **NTA-1** to **NTA-18**	270-271
5.15.	*In-silico* ADME prediction data of compounds **NTA-1** to **NTA-18**	272-273
5.16.	*In-silico* toxicity prediction data of compounds **NTA-1** to **NTA-18**	273-274
5.17.	*In-vitro* and computational MAO inhibition data for **MDA-1** to **MDA-14**	278-279
5.18.	*In-vitro* and computational AChE inhibition data for compounds **MDA-1** to **MDA-14**	287-288
5.19.	Neurotoxicity screening results of selected compounds of **MDA** series	295-296
5.20.	Antioxidant activity data of selected compounds of **MDA** series	296
5.21.	Estimation of biochemical parameters of **MDA-7** and **MDA-9**	297
5.22.	*In-silico* drug-likeness prediction studies for **MDA-1** to **MDA-14**	299
5.23.	*In-silico* ADME prediction data of compounds **MDA-1** to **MDA-14**	300-301
5.24.	*In-silico* toxicity prediction data of compounds **MDA-1** to **MDA-14**	302
5.25.	*In-vitro* and computational MAO inhibition data for **HPO-1** to **HPO-14**	306-307
5.26.	*In-vitro* and computational AChE inhibition data for compounds **HPO-1** to **HPO-1**	317
5.27.	Neurotoxicity screening results of selected compounds of **HPO** series	325-326
5.28.	Antioxidant activity data of selected compounds of **HPO** series	326

5.29.	Estimation of biochemical parameters of **HPO-7** and **HPO-9**	327
5.30.	*In-silico* drug-likeness prediction studies for **HPO-1** to **HPO-14**	329
5.31.	*In-silico* ADME prediction data of compounds **HPO-1** to **HPO-14**	330-331
5.32.	*In-silico* toxicity prediction data of compounds **HPO-1** to **HPO-14**	332